
CAS 863971-19-1
:Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
6 produtos.
Ref: IN-DA003RGK
5mg201,00€10mg229,00€50mgA consultar100mgA consultar250mgA consultar500mgA consultar(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-Y
CAS:(S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-Dioxo-2,5-Dihydro-1H-Pyrrol-1-Yl)-N-Methylhexanamido)-3-Methylbutanamido)-N,3-Dimethylbutanamido)-3-Methoxy-5-Methylheptanoyl)Pyrrolidin-2-YPureza:98%Peso molecular:925.16g/molMcMMAF
CAS:<p>McMMAF is a protective group-conjugated MMAF.</p>Fórmula:C49H76N6O11Pureza:99.65% - >99.99%Cor e Forma:SolidPeso molecular:925.16MC-MMAF
CAS:<p>MC-MMAF is an antibody that binds to the epidermal growth factor receptor (EGFR) on tumor cells and inhibits the proliferation of tumor cells by blocking the binding of epidermal growth factor. MC-MMAF has been shown to be an effective treatment for a variety of cancers, including breast cancer, lung cancer, head and neck cancer, and colorectal cancer. It is also being studied as a potential treatment for autoimmune diseases such as rheumatoid arthritis and psoriasis. MC-MMAF has been shown to improve prognosis in patients with glomerular filtration rate (GFR) less than 30 mL/min per 1.73 m2.</p>Fórmula:C49H76N6O11Pureza:Min. 95 Area-%Cor e Forma:White PowderPeso molecular:925.16 g/molMafodotin
CAS:Produto Controlado<p>Applications Mafodotin is an anticancer immunoconjugate for the diagnosis and treatment of cancer or B Cell proliferative diseases.<br>References Valliere-Douglass, J.F., et al.: Anal. Chem., 84, 2843 (2012); Alley, S.C., et al.: Bioconjugate. Chem., 19, 759 (2008); Doronina, S.O., et al.: Bioconjugate. Chem., 17, 114 (2006);<br></p>Fórmula:C49H76N6O11Cor e Forma:NeatPeso molecular:925.1613




